Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia

NCT00833976 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT00833976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00833976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
Lead sponsor
Massachusetts General Hospital
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2009
Completion date
March 31, 2013
Enrollment
65 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar disorder, high triglycerides, hypercholesterolemia, schizoaffective disorder, schizophrenia